Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting the highly attractive TNF receptor 2 (TNFR2) and widely regarded as a master control switch in immune modulation, as well as its pipeline of Treg candidates.
Lead Product(s): DT-001
Therapeutic Area: Immunology Product Name: DT-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fountain Healthcare Partners
Deal Size: $44.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 15, 2023